1. Home
  2. BIIB vs ARE Comparison

BIIB vs ARE Comparison

Compare BIIB & ARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • ARE
  • Stock Information
  • Founded
  • BIIB 1978
  • ARE 1994
  • Country
  • BIIB United States
  • ARE United States
  • Employees
  • BIIB N/A
  • ARE N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • ARE Real Estate Investment Trusts
  • Sector
  • BIIB Health Care
  • ARE Real Estate
  • Exchange
  • BIIB Nasdaq
  • ARE Nasdaq
  • Market Cap
  • BIIB 25.1B
  • ARE 19.3B
  • IPO Year
  • BIIB 1991
  • ARE 1997
  • Fundamental
  • Price
  • BIIB $159.59
  • ARE $106.78
  • Analyst Decision
  • BIIB Buy
  • ARE Buy
  • Analyst Count
  • BIIB 25
  • ARE 11
  • Target Price
  • BIIB $258.57
  • ARE $129.27
  • AVG Volume (30 Days)
  • BIIB 1.7M
  • ARE 1.1M
  • Earning Date
  • BIIB 10-30-2024
  • ARE 01-27-2025
  • Dividend Yield
  • BIIB N/A
  • ARE 4.81%
  • EPS Growth
  • BIIB 10.05
  • ARE 18.05
  • EPS
  • BIIB 11.06
  • ARE 1.64
  • Revenue
  • BIIB $9,607,500,000.00
  • ARE $3,085,452,000.00
  • Revenue This Year
  • BIIB N/A
  • ARE N/A
  • Revenue Next Year
  • BIIB N/A
  • ARE $2.15
  • P/E Ratio
  • BIIB $14.54
  • ARE $65.67
  • Revenue Growth
  • BIIB N/A
  • ARE 10.21
  • 52 Week Low
  • BIIB $153.62
  • ARE $102.89
  • 52 Week High
  • BIIB $268.30
  • ARE $135.45
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 35.98
  • ARE 39.43
  • Support Level
  • BIIB $158.44
  • ARE $102.89
  • Resistance Level
  • BIIB $165.29
  • ARE $112.42
  • Average True Range (ATR)
  • BIIB 3.97
  • ARE 1.84
  • MACD
  • BIIB 1.02
  • ARE 0.31
  • Stochastic Oscillator
  • BIIB 26.84
  • ARE 40.79

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About ARE Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Share on Social Networks: